Ibex Biosciences Launches Regulation D Campaign on Fundable

Quick Summary:

Gene Therapy Programs: Multiple preclinical gene therapy programs focus on the direct targeting of cancerous tumors and the mitigation of both chronic and acute inflammation.  The company's objectives include proactively identifying and assessing novel molecules and innovative methods for developing more potent therapeutics, as well as seeking out pioneering scientists and their early-stage discoveries to further product development objectives.

It has a robust pipeline of unique preclinical programs, further positioning it at the forefront of addressing numerous health issues currently affecting mankind like Malaria and numerous cancers.  Key Highlights of Ibex Biosciences: Antibody Research: Preclinical therapeutic antibody programs targeting Malaria and Oncology, with potential applications in treating inflammatory conditions.

North Bethesda, Maryland, Feb.03, 2025 (GLOBE NEWSWIRE) -- This recent move opens up investment opportunities for accredited investors looking to support cutting-edge research in antibodies, regeneration, and gene therapies.

Read Quick SummarySave Time

or

Article Details

Author / Journalist: Ibex Biosciences

Category: Technology

Markets: China

Topics: Biotech Research Support Ibex Regulation Company Therapies Developing Investors Campaign Biosciences

Source Website Secure: Yes (HTTPS)

News Sentiment: Negative

Fact Checked: Legitimate

Article Type: News Report

Published On: 2025-02-03 @ 22:30:00 (12 hours ago)

News Timezone: GMT +8:00

News Source URL: globenewswire.com

Language: English

Article Length: 193 words

Reading Time: 2 minutes read

Sentences: 9 lines

Sentence Length: 22 words per sentence (average)

Platforms: Desktop Web, Mobile Web, iOS App, Android App

Copyright Owner: © GlobeNewswire

News ID: 25850481

View Article Analysis

About GlobeNewswire

Main Topics: Technology

Official Website: globenewswire.com

Update Frequency: 64 posts per day

Year Established: 1998

Headquarters: China

News Last Updated: 8 hours ago

Coverage Areas: China

Ownership: Independent Company

Publication Timezone: GMT +8:00

Content Availability: Worldwide

News Language: English

RSS Feed: Available (XML)

API Access: Available (JSON, REST)

Website Security: Secure (HTTPS)

Publisher ID: #116

Publisher Details

Frequently Asked Questions